ADIL
Adial Pharmaceuticals, Inc.NASDAQHealthcare$1.69+3.55%ClosedMarket Cap: $1.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.37
P/S
0.00
EV/EBITDA
0.54
DCF Value
$7.97
FCF Yield
-386.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-182.3%
ROA
-117.3%
ROIC
-144.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-1.9M | $-2.0M | $-1.80 | — |
| FY 2025 | $0.00 | -Infinity% | $-7.8M | $-8.0M | $-11.93 | — |
| Q3 2025 | $0.00 | -Infinity% | $-1.8M | $-1.8M | $-2.00 | — |
| Q2 2025 | $0.00 | NaN% | $-1.9M | $-2.0M | $-4.50 | — |
| Q1 2025 | $0.00 | NaN% | $-2.3M | $-2.2M | $-8.50 | — |
| Q4 2024 | $0.00 | -Infinity% | $-1.9M | $-2.1M | $-2.75 | — |
| FY 2024 | $0.00 | NaN% | $-8.3M | $-13.2M | $-17.75 | — |
| Q3 2024 | $0.00 | NaN% | $-2.2M | $-2.2M | $-9.50 | — |
| Q2 2024 | $0.00 | -Infinity% | $-2.3M | $-2.5M | $-14.75 | — |
| Q1 2024 | $0.00 | NaN% | $-1.8M | $-6.5M | $-54.75 | — |
| Q4 2023 | $0.00 | -Infinity% | $-1.8M | $-1.9M | $-28.75 | — |
| FY 2023 | $0.00 | -Infinity% | $-6.9M | $-7.0M | $-136.00 | — |